Eli Lilly (NYSE: LLY) has become a market darling on the back of its remarkable success in the GLP-1 weight-loss drug category.
The company’s performance in recent quarters has been nothing short of extraordinary, driven almost entirely by demand for its flagship weight-loss and diabetes treatments.
In the second quarter of 2026, sales of Mounjaro surged 91% year over year, while Zepbound posted a still-impressive 46% gain in the same period.
The company also began generating revenue from its newly introduced Foundayo GLP-1 pill, adding another dimension to its already dominant position in the weight-loss drug market.
Taken together, those GLP-1 products produced nearly $15 billion of Eli Lilly’s nearly $23 billion in total quarterly revenue, representing close to two-thirds of the company’s entire top line.
That level of concentration in a single treatment category is a meaningful risk that investors cannot afford to ignore as the competitive pharmaceutical landscape continues to evolve.
Growth rates across the GLP-1 portfolio are already showing signs of moderation, which is a natural consequence of scaling a business to the size Eli Lilly has reached so quickly.
Zepbound’s sales grew 172% in the second quarter of 2025, a figure that has since moderated to 46% in the second quarter of 2026, illustrating how basic math begins to work against even the strongest growth stories over time.
Drug patents have finite durations, and the pharmaceutical industry is fiercely competitive, meaning the window for Eli Lilly to capitalize on its current GLP-1 advantage is not unlimited.
To its credit, Eli Lilly’s management has been aggressively reinvesting GLP-1 profits into acquisitions designed to expand the company’s presence in new treatment areas beyond weight loss.
That diversification strategy is widely regarded as the right move, though drug development is notoriously time-consuming and new candidates frequently fail to reach the market successfully.
Investors who focus solely on Eli Lilly’s current GLP-1 success risk being caught off guard when growth in that category inevitably begins to flatten or face fresh competitive pressure.
The three factors most worth watching are the outsized share of revenue tied to GLP-1 drugs, the slowing growth trajectory across that portfolio, and how effectively management deploys capital into new therapeutic areas.
Eli Lilly remains one of the most closely watched names in the pharmaceutical sector, but understanding the risks alongside the rewards is essential for any investor evaluating LLY shares today.
